Ensign Peak Advisors Inc Purchases 4,500 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Ensign Peak Advisors Inc boosted its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 95.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,201 shares of the company’s stock after purchasing an additional 4,500 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Soleno Therapeutics were worth $414,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. AlphaQuest LLC increased its position in shares of Soleno Therapeutics by 1,154.4% in the 4th quarter. AlphaQuest LLC now owns 715 shares of the company’s stock valued at $32,000 after buying an additional 658 shares in the last quarter. US Bancorp DE bought a new position in shares of Soleno Therapeutics during the 4th quarter valued at about $34,000. Avanza Fonder AB acquired a new position in shares of Soleno Therapeutics in the 4th quarter valued at approximately $76,000. Springhill Fund Asset Management HK Co Ltd bought a new stake in Soleno Therapeutics during the 4th quarter worth approximately $81,000. Finally, Avior Wealth Management LLC acquired a new position in shares of Soleno Therapeutics in the fourth quarter valued at approximately $89,000. Institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Stock Down 0.1%

Shares of NASDAQ SLNO opened at $75.01 on Friday. Soleno Therapeutics, Inc. has a twelve month low of $36.93 and a twelve month high of $80.99. The company has a market cap of $3.78 billion, a PE ratio of -22.59 and a beta of -2.67. The business’s 50 day moving average price is $66.28 and its two-hundred day moving average price is $55.06.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Wednesday, May 7th. The company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.19. As a group, research analysts anticipate that Soleno Therapeutics, Inc. will post -3.72 EPS for the current fiscal year.

Insider Buying and Selling at Soleno Therapeutics

In other news, CEO Bhatnagar Anish sold 699,095 shares of the stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $67.62, for a total transaction of $47,272,803.90. Following the sale, the chief executive officer now directly owns 577,076 shares of the company’s stock, valued at approximately $39,021,879.12. This represents a 54.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Patricia C. Hirano sold 3,782 shares of the company’s stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $70.11, for a total transaction of $265,156.02. Following the sale, the insider now directly owns 27,036 shares of the company’s stock, valued at $1,895,493.96. This represents a 12.27% decrease in their position. The disclosure for this sale can be found here. Insiders sold 942,672 shares of company stock valued at $64,058,781 in the last quarter. Company insiders own 12.30% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on SLNO. Guggenheim raised their price objective on shares of Soleno Therapeutics from $81.00 to $97.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. Cantor Fitzgerald lifted their price objective on shares of Soleno Therapeutics from $67.00 to $123.00 and gave the company an “overweight” rating in a report on Thursday, March 27th. Laidlaw increased their target price on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, March 27th. Piper Sandler lifted their price target on shares of Soleno Therapeutics from $93.00 to $145.00 and gave the company an “overweight” rating in a research note on Thursday, April 24th. Finally, UBS Group set a $105.00 price objective on shares of Soleno Therapeutics in a research note on Thursday, March 27th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $106.78.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.